CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Circulating antigen-primed cytotoxic T-cells in patients with renal tumors treated with surgery.
Circulating antigen-primed cytotoxic T-cells in patients with renal tumors treated with surgery.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肾切除术与细胞溶解性抗原致敏 CD8+ T 细胞增加及特定的 PBMC 谱变化相关。
研究纳入2016至2018年接受肾切除术的局限性或转移性实体肾肿块患者。在术前、术后1天和术后3个月采集血样用于PBMC分析。通过流式细胞术鉴定CD11a高表达的CD8⁺ T淋巴细胞，并进一步根据CX3CR1/GZMB、Ki67、Bim和PD-1表达进行表征。采用Wilcoxon符号秩检验评估术前至术后1天和3个月循环CD8⁺ T细胞的变化。
在肾细胞癌患者中，手术后3个月抗原启动型CX3CR1⁺GZMB⁺ T细胞显著增加（增加0.8×10⁹个细胞，P=.01）。相反，3个月时Bim⁺ T细胞绝对数下降（减少1.9×10⁹个细胞，P=.02）。PD-1⁺细胞（减少1.4×10⁹个，P=.7）和CD11a高表达CD8⁺ T淋巴细胞（增加1.3×10⁹个，P=.9）的绝对数无显著变化。Ki67⁺ T细胞至3个月时减少（减少0.8×10⁹个，P<.001）。
肾切除术与溶细胞性抗原启动CD8⁺ T细胞增加及特定PBMC谱变化相关。仍需进一步研究以确定手术在恢复抗肿瘤免疫方面可能发挥的作用。
Patients with localized or metastatic solid renal masses who underwent nephrectomy from 2016 to 2018 were enrolled. Blood samples were collected at 3 timepoints for PBMCs analysis (pre-op, 1 day, and 3 months post-op). Flow cytometry was used to identify CD11a high CD8+ T lymphocytes that were then further characterized according to the expression of CX3CR1/GZMB, Ki67, Bim, and PD-1. Changes in circulating CD8+ T-cells from pre-op to 1 day and 3 months post-op were evaluated using Wilcoxon signed rank tests.
Antigen-primed CX3CR1+GZMB+ T-cells significantly increased by 3 months after surgery among patients with RCC (0.8 × 10 9 cells; P = 0.01). In contrast, there was a decrease in absolute numbers of Bim+ T-cells at 3 months (-1.9 × 10 9 cells; P = 0.02). There were no significant absolute changes in PD-1+ (-1.4 × 10 9 ; P = 0.7) and CD11a high CD8+ T lymphocytes (1.3 × 10 9 ; P = 0.9). Ki67+ T-cells decreased by 3 months (-0.8 × 10 9 ; P < 0.001).
Nephrectomy is associated with an increase in cytolytic antigen-primed CD8+ T-cells and specific PBMC profile changes. Further studies are warranted to ascertain the role surgery may have in the restoration of anti-tumor immunity.
MEMBER ACCOUNT
登录成功会直接打开下一页。
